During the past decade, Washington University School of Medicine Siteman Cancer Center conducted 85 clinical trials. In the 10-year time frame, 85 clinical trials started and 35 clinical trials were completed, i.e. on average, 41.2% percent of trials that started reached the finish line to date. In the past 5 years, 42 clinical trials started and 14 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Washington University School of Medicine Siteman Cancer Center" #1 sponsor was "National Cancer Institute (NCI)" with 9 trials, followed by "Celgene" with 7 trials sponsored, "Hoosier Cancer Research Network" with 7 trials sponsored, "Novartis Pharmaceuticals" with 7 trials sponsored and "Alliance for Clinical Trials in Oncology" with 7 trials sponsored. Other sponsors include 112 different institutions and companies that sponsored additional 94 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Washington University School of Medicine Siteman Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 22 trials as a collaborator, "Merck Sharp & Dohme LLC" with 9 trials as a collaborator, "Hoosier Cancer Research Network" with 8 trials as a collaborator, "Walther Cancer Institute" with 8 trials as a collaborator and "Sanofi" with 5 trials as a collaborator. Other collaborators include 75 different institutions and companies that were collaborators in the rest 68 trials.

According to Clinical.Site data, the most researched conditions in "Washington University School of Medicine Siteman Cancer Center" are "Breast Cancer" (11 trials), "Colorectal Cancer" (7 trials), "Metastatic Cancer" (7 trials), "HIV Infection" (6 trials) and "Lung Cancer" (6 trials). Many other conditions were trialed in "Washington University School of Medicine Siteman Cancer Center" in a lesser frequency.

Most popular intervention types in "Washington University School of Medicine Siteman Cancer Center" are "Drug" (130 trials), "Other" (24 trials), "Biological" (22 trials), "Procedure" (12 trials) and "Radiation" (10 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (9 trials), "Nivolumab" (8 trials), "Pharmacological Study" (7 trials), "Placebo" (7 trials) and "Rituximab" (7 trials). Other intervention names were less common.

The vast majority of trials in "Washington University School of Medicine Siteman Cancer Center" are 134 trials for "All" genders, 13 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Washington University School of Medicine Siteman Cancer Center". undefined are not yet recruiting, 32 are recruiting, 32 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 64 completed trials in Washington University School of Medicine Siteman Cancer Center, undefined suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in Washington University School of Medicine Siteman Cancer Center, 54 "Phase 1" clinical trials were conducted, 76 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 8 trials that are defined as “Not Applicable".